Necrobiotic xanthogranuloma (NXG) is a chronic, progressive non-Langerhans histiocytic granulomatous disease. While case reports describing periorbital involvement of NXG are frequent, only a few case reports describing ocular involvement, such as scleritis and uveitis, exist. Herein, we present a case presenting initially as bilateral anterior and posterior scleritis, as well as a chronic bilateral granulomatous panuveitis, and discuss the immunosuppressant options that should be considered for this disease with protean manifestations.
Get full access to this article
View all access options for this article.
References
1.
KossardS., and WinkelmannR.K.Necrobiotic xanthogranuloma with paraproteinemia. J. Am. Acad. Dermatol., 3:257–270, 1980.
2.
WinkelmannR.K.Cutaneous syndromes of non-X histiocytosis. A review of the macrophage-histiocyte diseases of the skin. Arch. Dermatol., 117:667–672, 1981.
3.
SpicknallK.E., and MehreganD.A.Necrobiotic xanthogranuloma. Int. J. Dermatol., 48:1–10, 2009.
4.
FinanM.C., and WinkelmannR.K.Necrobiotic xanthogranuloma with paraproteinemia. A review of 22 cases. Medicine., 65:376–388, 1986.
5.
MehreganD.A., and WinkelmannR.K.Necrobiotic xanthogranuloma. Arch. Dermatol., 128:94–100, 1992.
6.
NovakP.M., RobbinsT.O., and WinkelmannR.K.Necrobiotic xanthogranuloma with myocardial lesions and nodular transformation of the liver. Hum. Pathol., 23:195–196, 1992.
7.
HigginsL.S., GoR.S., DingliD., et al.Clinical features and treatment outcomes of patients with necrobiotic xanthogranuloma associated with monoclonal gammopathies. Clin. Lymphoma Myeloma Leuk., 16:447–452, 2016.
8.
PeymanA., WalshN., GreenP., DoreyM.W., SeamoneC., and PasternakS.Necrobiotic xanthogranuloma associated with necrotizing scleritis. Am. J. Dermatopathol., 34:644–647, 2012.
9.
WilhelmusK.R., YenM.T., RiceL., and FontR.L.Necrobiotic xanthogranuloma with posterior scleritis. Arch. Ophthalmol., 124:748, 2006.
10.
Al-BermaniA., FigueiredoF., SpeightE.L., JacksonG.H., and PanditR.Necrobiotic xanthogranuloma masquerading as posterior scleritis. Eye (Lond.), 23:239–240, 2009.
11.
ZelgerB., EisendleK., MensingC., and ZelgerB.Detection of spirochetal micro-organisms by focus-floating microscopy in necrobiotic xanthogranuloma. J. Am. Acad. Dermatol., 57:1026–1030, 2007.
12.
VasconcelosF.O., OliveiraL.A., NavesM.D., CastroW.H., and GomezR.S.Juvenile xanthogranuloma: case report with immunohistochemical identification of early and late cytomegalovirus antigens. J. Oral Sci., 43:21–25, 2001.
13.
AdamZ., ZahradovaL., KrejciM., et al.[Diffuse plane normolipemic xanthomatosis and necrobiotic xanthogranuloma associated with monoclonal gammopathy—determining the disease stage with PET-CT and treatment experience. Two case studies and literature review]. Vnitrni lekarstvi., 56:1158–1168, 2010.
14.
MatsuuraF., YamashitaS., HiranoK., et al.Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia—a possible pathogenesis of necrobiotic xanthogranuloma. Atherosclerosis. 142:355–365, 1999.
15.
KerstetterJ., and WangJ.Adult orbital xanthogranulomatous disease: a review with emphasis on etiology, systemic associations, diagnostic tools, and treatment. Dermatol. Clin., 33:457–463, 2015.
16.
SagginiA., CotaC., and CerroniL.Distinctive pattern of adipophilin expression in necrobiotic xanthogranuloma. Am. J. Dermatopathol., 38:468–470, 2016.
17.
SchulmanJ.M., and LeBoitP.E.Adipophilin expression in necrobiosis lipoidica, granuloma annulare, and sarcoidosis. Am. J. Dermatopathol., 37:203–209, 2015.
18.
TakahashiK., and NaitoM.Lipid storage disease: part I. Ultrastructure of xanthoma cells in various xanthomatous diseases. Acta Pathol. Jap., 33:959–977, 1983.
19.
SamtsovA.V.Cutaneous sarcoidosis. Int. J. Dermatol., 31:385–391, 1992.
20.
IannuzziM.C., and FontanaJ.R.Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 305:391–399, 2011.
21.
KattaR.Cutaneous sarcoidosis: a dermatologic masquerader. Am. Fam. Phys., 65:1581–1584, 2002.
22.
CodereF., LeeR.D., and AndersonR.L.Necrobiotic xanthogranuloma of the eyelid. Arch. Ophthalmol., 101:60–63, 1983.
23.
JonesR.E., and ChathamW.W.Update on sarcoidosis. Curr. Opin. Rheumatol., 11:83–87, 1999.
24.
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am. J. Respir. Crit. Care Med., 160:736–755, 1999.
25.
JonesJ.V., CummingR.H., and AsplinC.M.Evidence for circulating immune complexes in erythema nodosum and early sarcoidosis. Ann. N. Y. Acad. Sci., 278:212–219, 1976.
26.
HedforsE., and NorbergR.Evidence for circulating immune complexes in sarcoidosis. Clin. Exp. Immunol., 16:493–496, 1974.
27.
YanardagH., PamukG.E., KarayelT., and DemirciS.Bone marrow involvement in sarcoidosis: an analysis of 50 bone marrow samples. Haematologia. 32:419–425, 2002.
28.
LiX., MaY., TangJ., ChenT., and MaX.A hemophagocytic lymphohistiocytosis patient that presented with unilateral panuveitis. Ocul. Immunol. Inflamm.1–3, 2016.
29.
FukayaS., YasudaS., HashimotoT., et al.Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford). 47:1686–1691, 2008.
30.
AlperJ., and KegelM.Skin signs in pulmonary disease. Clin. Chest Med., 8:299–311, 1987.
31.
BeermanH., and KirshbaumB.A.Some associated pulmonary and cutaneous diseases. A review of recent literature. Am. J. Med. Sci., 242:494–517, 1961.
32.
FranquetT., GimenezA., CaceresJ., SabateJ.M., and NadalC.Imaging of pulmonary-cutaneous disorders: matching the radiologic and dermatologic findings. Radiographics. 16:855–869, 1996.
33.
GoetteD.K., and PrescottC.E.Late benign syphilis of the skin. Southern Med. J., 71:505–508, 1978.
34.
CombesF.C.Tertiary syphilis with multiple gummas of skin and bones responding poorly to penicillin therapy. A.M.A. Arch. Dermatol. Syphilol., 63:138–140, 1951.
35.
ElnerV.M., MintzR., DemirciH., and HassanA.S.Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Trans. Am. Ophthalmol. Soc., 103:69–73; discussion 73–64, 2005.
36.
ChaveT.A., ChowdhuryM.M., and HoltP.J.Recalcitrant necrobiotic xanthogranuloma responding to pulsed high-dose oral dexamethasone plus maintenance therapy with oral prednisolone. Br. J. Dermatol., 144:158–161, 2001.
UgurluS., BartleyG.B., and GibsonL.E.Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am. J. Ophthalmol., 129:651–657, 2000.
39.
JabsD.A., RosenbaumJ.T., FosterC.S., et al.Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol., 130:492–513, 2000.
40.
GangaputraS., NewcombC.W., LiesegangT.L., et al.Methotrexate for ocular inflammatory diseases. Ophthalmology. 116:2188–2198.e2181, 2009.
41.
ThorneJ.E., JabsD.A., QaziF.A., NguyenQ.D., KempenJ.H., and DunnJ.P.Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 112:1472–1477, 2005.
42.
PasadhikaS., KempenJ.H., NewcombC.W., et al.Azathioprine for ocular inflammatory diseases. Am. J. Ophthalmol., 148:500–509.e502, 2009.
43.
RathinamS.R., BabuM., ThundikandyR., et al.A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 121:1863–1870, 2014.
44.
HaydenA., WilsonD.J., and RosenbaumJ.T.Management of orbital xanthogranuloma with methotrexate. Br. J. Ophthalmol., 91:434–436, 2007.
45.
EfeberaY., BlanchardE., AllamC., HanA., LeeS., and MunshiN.Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin. Lymphoma Myeloma Leuk., 11:298–302, 2011.
46.
SilapuntS., and ChonS.Y.Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. J. Drugs Dermatol., 9:273–276, 2010.
47.
DireskeneliH., ErgunT., YavuzS., HamuryudanV., and Eksioglu-DemiralpE.Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin. Rheumatol., 27:373–375, 2008.
48.
GalustianC., MeyerB., LabartheM.C., et al.The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother., 58:1033–1045, 2009.
49.
HideshimaT., ChauhanD., ShimaY., et al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 96:2943–2950, 2000.
50.
SheskinJ., and ZaubermanH.Iridocyclitis in lepra reaction treated with thalidomide. Leprosy Rev. 41:233–235, 1970.
51.
ParentinF., Da PozzoS., LeporeL., and PerissuttiP.Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child. Ophthalmologica. 215:70–73, 2001.
52.
Guex-CrosierY., PittetN., and HerbortC.P.The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats. Graefes Arch. Clin. Exp. Ophthalmol., 233:90–93, 1995.
53.
PorstmannA.U., ZwingenbergerK., PleyerU., and BaatzH.Effects of a new immunotherapeutic agent (CG5601) on endotoxin-induced uveitis. Ophthalmic Res. 35:143–149, 2003.
54.
RodriguesG.B., PassosG.F., Di GiuntaG., et al.Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats. Exp. Eye Res., 84:553–560, 2007.
55.
HamzaM.H.Treatment of Behcet's disease with thalidomide. Clin. Rheumatol., 5:365–371, 1986.
56.
GreenJ., UpjohnE., McCormackC., ZeldisJ., and PrinceH.M.Successful treatment of Behcet's disease with lenalidomide. Br. J. Dermatol., 158:197–198, 2008.
57.
YasuiK., UchidaN., AkazawaY., et al.Thalidomide for treatment of intestinal involvement of juvenile-onset Behcet disease. Inflamm. Bowel Dis., 14:396–400, 2008.
58.
MachadoS., AlvesR., LimaM., LealI., and MassaA.Cutaneous necrobiotic xanthogranuloma (NXG)—successfully treated with low dose chlorambucil. Eur. J. Dermatol., 11:458–462, 2001.
59.
LuckJ., LaytonA., and NobleB.A.Necrobiotic xanthogranuloma with orbital involvement. J. R. Soc. Med., 85:357–358, 1992.
60.
MeyerS., SzeimiesR.M., LandthalerM., and HohenleutnerS.Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinemia and ocular involvement. Br. J. Dermatol., 153:443–445, 2005.
61.
HallermannC., TittelbachJ., NorgauerJ., and ZiemerM.Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. Arch. Dermatol., 146:957–960, 2010.
62.
WeiY.H., ChengJ.J., WuY.H., et al.Necrobiotic xanthogranuloma: response to dapsone. Dermatol. Ther., 28:7–9, 2015.
63.
MeyerS., LandthalerM., and HohenleutnerS.[Long-term course of necrobiotic xanthogranuloma with ocular involvement]. Hautarzt. 57:144–149, 2006.
64.
RogersR.S., III, SeehaferJ.R., and PerryH.O.Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J. Am. Acad. Dermatol., 6:215–223, 1982.
65.
GeorgiouS., MonastirliA., KapranosN., PasmatziE., SakkisT., and TsambaosD.Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. Acta Derm. Venereol., 79:484–485, 1999.
66.
VenencieP.Y., Le BrasP., ToanN.D., TcherniaG., and DelfraissyJ.F.Recombinant interferon alfa-2b treatment of necrobiotic xanthogranuloma with paraproteinemia. J. Am. Acad. Dermatol., 32:666–667, 1995.
67.
LiszewskiW., WisniewskiJ.D., SafahH., and BohE.E.Treatment of refractory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin. Dermatol. Ther., 27:268–271, 2014.
68.
RayA., Sassone-CorsiP., and SehgalP.B.A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation. Mol. Cell. Biol., 9:5537–5547, 1989.
69.
LiP., SanzI., O'KeefeR.J., and SchwarzE.M.NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes. J. Immunol. (Baltimore)., 164:5990–5997, 2000.
70.
HideshimaT., ChauhanD., PodarK., SchlossmanR.L., RichardsonP., and AndersonK.C.Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol., 28:607–612, 2001.
71.
SuhlerE.B., LimL.L., BeardsleyR.M., et al.Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 121:1885–1891, 2014.
72.
CaoJ.H., OrayM., CochoL., and FosterC.S.Rituximab in the treatment of refractory noninfectious scleritis. Am. J. Ophthalmol., 164:22–28, 2016.
73.
RubinsteinA., WolfD.J., and GransteinR.D.Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. J. Cutan. Med. Surg., 17:347–350, 2013.
74.
NambudiriV.E., McLaughlinC., LoT.C., ZembowiczA., and MoschellaS.Successful multimodality treatment of recalcitrant necrobiotic xanthogranuloma using electron beam radiation and intravenous immunoglobulin. Clin. Exp. Dermatol., 41:179–182, 2016.
75.
JakobiecF.A., MillsM.D., HidayatA.A., et al.Periocular xanthogranulomas associated with severe adult-onset asthma. Trans. Am. Ophthalmol. Soc., 91:99–125; discussion 125–129, 1993.
76.
CharD.H., LeBoitP.E., LjungB.M., and WaraW.Radiation therapy for ocular necrobiotic xanthogranuloma. Arch. Ophthalmol., 105:174–175, 1987.
77.
JordanM.B., AllenC.E., WeitzmanS., FilipovichA.H., and McClainK.L.How I treat hemophagocytic lymphohistiocytosis. Blood. 118:4041–4052, 2011.
78.
ReddyV.C., SalomaoD.R., GarrityJ.A., BaratzK.H., and PatelS.V.Periorbital and ocular necrobiotic xanthogranuloma leading to perforation. Arch. Ophthalmol., 128:1493–1494, 2010.
79.
SchaudigU., and Al-SamirK.Upper and lower eyelid reconstruction for severe disfiguring necrobiotic xanthogranuloma. Orbit. 23:65–76, 2004.
80.
MohseninA., SinardJ., HuangJ.J.Necrobiotic xanthogranuloma and chronic lymphocytic leukemia of the conjunctiva masquerading as scleritis and uveitis. Clin. Ophthalmol., 6:2045–2047, 2012.
